The probability of NCI receiving a boost in funds over the next two years is slim, NCI Director Monica Bertagnolli said at the joint meeting of the National Cancer Advisory Board and Board of Scientific Advisors June 14.
I have spent over 20 years running a tumor imaging metrics core at an academic cancer center. In that time, I have watched clinical trial enrollment concentrate at a relatively small number of flagship academic institutions. Unfortunately, trials do not propagate well to the community sites where most patients prefer to receive care. The explanations usually offered for why this happens have never fully accounted for what I observed.
